The Immunological Therapeutic Strategies for Controlling Multiple Sclerosis: Considerations during the COVID-19 Pandemic.

Azimzadeh, Maryam ORCID; Möhn, Nora ORCID; Ghane Ezabadi, Sajjad ORCID; Shams Esfandabadi, Zahra ORCID; Soleimani, Alireza ORCID; Ranjbar, Elaheh ORCID; Jahromi, Maliheh; Seyedebrahimi, Reihaneh; Skripuletz, Thomas ORCID; Moharrami Kasmaie, Farshad

A growing body of evidence initially suggested that patients with multiple sclerosis (MS) might be more susceptible to coronavirus disease 2019 (COVID-19). Moreover, it was speculated that patients with MS treated with immunosuppressive drugs might be at risk to develop a severe diseases course after infection with the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV2). However, the recently published data have shown that MS patients do not have a higher risk for severe COVID-19. Although there is no indication that patients with MS and immunomodulatory/immunosuppressive therapy are generally at a higher risk of severe COVID-19, it is currently being emphasized that the hazards of poorly treated MS may outweigh the putative COVID-19 dangers. In this review, we discuss the challenges and considerations for MS patients in the COVID-19 pandemic.

Cite

Citation style:

Azimzadeh, Maryam / Möhn, Nora / Ghane Ezabadi, Sajjad / et al: The Immunological Therapeutic Strategies for Controlling Multiple Sclerosis: Considerations during the COVID-19 Pandemic.. 2021.

Access Statistic

Total:
Downloads:
Abtractviews:
Last 12 Month:
Downloads:
Abtractviews:

open graphic

Rights

Use and reproduction:

Export